![](/img/cover-not-exists.png)
2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation
Sepúlveda, J.M., Vaz, M.A., Gil, M., Reynés, G., Gallego, O., Bolós, M.V., Laýn, A. Hernádez, Sánchez-Gómez, P., Martýnez, M., Vicente, E., Quindos, M., Luque, R., Ramos, A., Ruano, Y., Manneh, R., SeVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31619-7
Date:
September, 2015
File:
PDF, 59 KB
english, 2015